Cd20 binding molecules
CA 2525139 C · Owner: Ondek, Brian · Inventors: Davies, Julian; Allan, Barrett W.; Ondek, Brian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular the present , invention relates to CD20 binding molecules with a high binding affinity and , a low dissociation rate, with regard to human CD20. Preferably the CD20 , binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 20, 2004 and granted December 4, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 20, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 20, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.